Regen BioPharma Presented Novel Therapeutic Target for Leukemia and Myelodysplastic Syndrome at the American Society of Hematology Annual Meeting
Regen Sees Feedback From Presentation and Potential Collaborations Stemming From Conference Invaluable in Further Expansion of the Company's Research
SAN DIEGO, CA--(Marketwired - Dec 11, 2014) - Regen BioPharma Inc. (OTC PINK: RGBP) announced today it presented data demonstrating NR2F6, a new drug target, is essential in development and maintenance of leukemia and myelodysplastic syndrome at the American Society of Hematology Annual Meeting. This new drug target was identified by the Company's senior research consultant, Dr. Christine Ichim. A drug target is a gene involved in a disease which researchers aim to inhibit its function in order to treat the disease. Regen recently acquired intellectual property generated at the University of Toronto for inhibiting NR2F6.
The work entitled "NR2F6 (EAR-2) Is a Novel Leukemia Oncogene Whose Cellular Function Is to Regulate Terminal Differentiation of Erythrocytes at the Proerythroblast Stage" was presented as abstract #1337 at the Moscone Center in San Francisco on Saturday, December 6th, 2014 by Dr. Christine Ichim, Senior Research Consultant to Regen.
"Acceptance of this work by the scientific committee of the American Society of Hematology (ASH) for presentation provides a strong signal the scientific community is supportive of this novel area of investigation," said Dr. Thomas Ichim, the Company's Chief Scientific Officer. "We believe that the data presented was well received by industry and academic groups, giving the company excellent exposure, and opportunities to network and collaborate with some of the world's top physicians, scientists and pharmaceutical companies."
"We congratulate Dr. Christine Ichim and her collaborator, Dr. Richard A. Wells, hematologist from the University of Toronto, who tirelessly worked for years at generating these data. The findings presented are the subject of intellectual property that Regen has recently purchased through an assignment agreement," said David Koos, Chairman and CEO of Regen. "Essentially, the data demonstrated that the gene NR2F6 is key for creation of leukemia and myelodysplastic syndrome. Utilizing gene silencing and small molecule inhibitors, the company is working on developing a new class of drugs that kill cancer at the level of the cancer stem cells. These are anticipated to be more effective and lack the substantial toxicity of existing chemotherapies."
The American Society of Hematology is the world's largest professional society dealing with the causes and treatment of blood disorders. The ASH Annual Conference is the premier meeting discussing normal and malignant blood disorders. There were more than 18,000 physicians and scientists, as well as more than 300 pharmaceutical companies, medical suppliers, clinical diagnostic and research-based companies, publishers, and nonprofit organizations from 50 states and nearly 100 countries outside the United States1 in attendance.
About Regen BioPharma Inc.: Regen BioPharma Inc. (OTC PINK: RGBP) is a majority owned subsidiary of Bio-Matrix Scientific Group, Inc. (OTC PINK: BMSN). Regen is a biotechnology company focused on identifying undervalued regenerative medicine applications in the stem cell space and rapidly advancing these technologies through pre-clinical and Phase I/ II clinical trials. Currently the Company is focused on developing treatments for Aplastic Anemia and a gene silencing therapy for treating cancer. For more information refer to the company's website http://www.regenbiopharma.com/
Disclaimer: This news release may contain forward-looking statements. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified. Future events and actual results could differ materially from those set forth in, contemplated by, or underlying the forward-looking statements. The risks and uncertainties to which forward looking statements are subject include, but are not limited to, the effect of government regulation, competition and other material risks.
